admin, Author at PsyNews.com

Home Authors Posts by admin

2176 POSTS 0 COMMENTS

https://psynews.com

Psychedelic Bulletin #111 – Psychedelics on Netflix; House Adopts 2 Psychedelic...

MDMA: Rolling from Counterculture to the Clinic Counter

PT337 – Lauren Katalinich & Anya Oleksiuk – The Psychedelic Society:...

Silo Pharma Announces Positive Results in Subcutaneous Delivery of its Novel...

Optimi Health Finalizes Psilocybin Supply Agreement With Bloom Psychedelic Therapy And...

PharmaTher Announces Notice of Allowance for U.S. Patent Covering Ketamine for...

FILAMENT HEALTH ISSUED THIRD PATENT BY UNITED STATES PATENT AND TRADEMARK...

PT336 – Sisi Li, Ph.D. – Porta Sophia: Psychedelic Prior Art

Algernon Pharmaceuticals Provides Update on its Planned Phase 1 Repirinast Chronic...

Psychedelic Research Bulletin: June 2022

1...134135136...218 Page 135 of 218

EDITOR PICKS

After the Readout: How the Field Is Interpreting Compass’ Phase 3...

Q1’26 Psychedelic Drug Development Pipeline: Bullseye Charts

Compass Provides Fuller Phase 3 Picture, MADRS Curves, on Webcast

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

admin